University of Nevada

Research Development Foundation

Other

University of Minnesota

The University of New Mexico

Board of Regents of the Nevada System of Higher Education

Nevada Research & Innovation Corporation

Thomas R Kozel

Bruce Robert Blazar

William J Murphy

Julie A Lovchik

Peter Thorkildson

Ann Percival

Suzanne Brandt

David P AuCoin

Claire Smalley

Sherri L Bloomer

C Rick Lyons

Anne C Savoy

Amanda Burnham-Marusich

David Aucoin

Breeana Hubbard

C Richard Lyons

Non-invasive methods are provided herein for diagnosing samples as including a fungus, including fungal infection or contamination, with specific monoclonal antibodies capable of detecting molecules associated with fungi in the sample, such as a biological or environmental sample. These molecules can be identified using various methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), or a lateral flow immunoassay.

Fungal detection using mannan epitope

Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals againstor other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused byor other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.

Detection, prevention, and treatment of anthrax and other infectious diseases

Non-invasive methods are provided herein for the diagnosis of melioidosis with specific antibodies capable of detecting molecules associated with melioidosis in a biological fluid, such as urine or serum. These molecules can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. Methods of inducing an immune response to melioidosis are also disclosed. The methods include the use of the immunogenic melioidosis polypeptides, nucleic acids encoding these polypeptides, and/or viral vectors encoding an immunogenic melioidosis polypeptide, alone or in conjunction with other agents, such as traditional melioidosis therapies. Also disclosed are methods for treating a subject having melioidosis. These methods include inducing an immune response to melioidosis and/or using an inhibitory nucleic acid, such as a siRNA or antisense molecule, to decrease a melioidosis associated molecule expression in order to treat melioidosis.

Method of diagnosing and treating melioidosis

Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a verterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a-associated condition, such as melioidosis. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by, such as meliodosis.

Method of detecting and identifying circulating antigens in human biological samples

Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a veterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a-associated condition, such as melioidosis. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by, such as meliodosis.

Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases

The present invention provides a novel enzyme which de-O-acetylates glucuronoxylomannan of,and a gene encoding such enzyme. Also provided are applications of such enzyme in treating cryptococcosis.

Glucuronoxylomannan (GXM)-O-acetylhydrolase of Cryptococcus neoformans and uses thereof

The present invention provides a novel enzyme which de-O-acetylates glucuronoxylomannan of Cryptococcus neoformans and a gene encoding such enzyme. Also provided are applications of such enzyme in treating cryptococcosis.

Glucuronoxylomannan (GXM)-O-acetylhydrolase of cryptococcus neoformans

The present invention provides a method of identifying immunocompromised individuals who are at high risk for development of cryptococcosis, comprising the step of measuring the levels of IgG antibody to glucuronoxylomannan in the sera of said individuals. Also provided are various methods of detecting antibody to glucuronoxylomannan in sera and a kit for assaying the presence of antibody to glucuronoxylomannan in the sera of immunocompromised individuals.

Growing community of inventors

Reno, NV, United States of America

Thomas R Kozel